Ingredient or product comparison
GHK-Cu Studied Scalp Inflammation: Comparison of Mechanisms and Outcomes
Understanding how GHK-Cu compares to conventional anti-inflammatory treatments clarifies its unique therapeutic value. GHK-Cu (1–2% topical) NF-κB inhibition + TGF-β activation 39–47% reduction in TNF-α, IL-1β, IL-6 (4–8 weeks) Significant collagen synthesis,
This source-based comparison does not add ratings or recommend a winner.
- Understanding how GHK-Cu compares to conventional anti-inflammatory treatments clarifies its unique therapeutic value.
- GHK-Cu (1–2% topical)
- NF-κB inhibition + TGF-β activation
- 39–47% reduction in TNF-α, IL-1β, IL-6 (4–8 weeks)
- Significant collagen synthesis, increased dermal thickness, angiogenesis
- <5% (mild irritation)
- Gold standard for conditions requiring both inflammation control and structural repair; copper dependence requires stable formulation
- Ketoconazole (1–2% topical)
- Antifungal (Malassezia suppression) + mild anti-inflammatory
- 20–28% reduction in IL-1β (fungal-mediated cases only)
- None documented
- 8–12% (contact dermatitis, dryness)
- Effective for fungal-driven seborrheic dermatitis but does not address non-fungal inflammation or repair damaged tissue
- Corticosteroid (0.1% betamethasone)
- Glucocorticoid receptor agonism (broad immunosuppression)
- 50–65% reduction across all inflammatory cytokines (acute phase)
- Negative (long-term use causes dermal atrophy, collagen breakdown)
- 15–25% (skin thinning, rebound flare, tachyphylaxis)
- Potent short-term but contraindicated for chronic use due to structural damage and rebound inflammation upon cessation
- Salicylic acid (2–3% topical)
- Keratolytic (removes dead skin) + mild anti-inflammatory (COX inhibition)
- 10–15% reduction in surface inflammatory markers
- None
- 10–15% (dryness, peeling, irritation)
- Symptomatic relief for scaling but minimal effect on underlying inflammation; does not promote repair